Koninklijke Philips N.V. (PHG)
After hours:
| Previous close | 20.99 |
| Open | 21.13 |
| Bid | 20.66 x 1800 |
| Ask | 21.50 x 1300 |
| Day's range | 20.98 - 21.24 |
| 52-week range | 20.20 - 48.72 |
| Volume | |
| Avg. volume | 2,064,716 |
| Market cap | 18.827B |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | 37.77 |
| EPS (TTM) | 0.56 |
| Earnings date | N/A |
| Forward dividend & yield | 0.91 (4.35%) |
| Ex-dividend date | 12 May 2022 |
| 1y target est | 45.07 |
- GlobeNewswire
Philips completes cancellation of 8.8 million shares
July 4, 2022Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has completed the cancellation of 8,758,455 of its shares. The cancelled shares were acquired as part of the EUR 1.5 billion share repurchase program for capital reduction purposes that was announced on July 26, 2021.Philips’ current issued share capital amounts to EUR 177,863,016.40 representing 889,315,082 common shares. As communicated earlier, Philips intends to have 19,571,218 shares delive
- Business Wire
Philips Signs Health Care Sector Pledge to Reduce Emissions as part of Department of Health and Human Services, White House Initiative
CAMBRIDGE, Mass., July 01, 2022--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the company has joined an initiative created by the Department of Health and Human Services (HHS), in partnership with the White House, to address climate action through the reduction of greenhouse gas emissions. Earlier this week at the White House, Philips along with other health sector organizations and administration leaders, participated in a roundtable discussion abo
- GlobeNewswire
Philips incorporates Biodesix blood-based proteomic nodule risk assessment testing into Lung Cancer Orchestrator to advance early lung cancer diagnosis
Lung Cancer Orchestrator June 30, 2022Solution adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis and treatment Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has teamed up with Biodesix, Inc. (Colorado, U.S.) (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, to incorporate th
